Your browser doesn't support javascript.
loading
Geraniin as a potential inhibitor of SARS-CoV-2 3CLpro.
Yu, Wen-Di; Jin, Qi-Ying; Zeng, Mao-Sen; Liu, Jin-Yuan; Xu, Pei-Ping.
Afiliación
  • Yu WD; Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, P.R. China.
  • Jin QY; Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, P.R. China.
  • Zeng MS; Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, P.R. China.
  • Liu JY; Basic Medical College, Guangzhou University of Chinese Medicine, Guangzhou, P.R. China.
  • Xu PP; Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, P.R. China.
Nat Prod Res ; 36(23): 6060-6063, 2022 Dec.
Article en En | MEDLINE | ID: mdl-35200071
ABSTRACT
Geraniin is a polyphenolic compound first isolated from Geranium thunbergii. The major protease (Mpro), namely 3 C-like protease (3CLpro), of coronaviruses is considered an attractive drug target as it is essential for the processing and maturation of viral polyproteins. Thus, our primary goal is to explore the efficiency of geraniin on 3CLpro of SARS-CoV-2 using the computational biology strategy. In this work, we studied the anti-coronavirus effect of geraniin in vitro and its potential inhibitory mode against the 3CLpro of SARS-CoV-2. We found that geraniin inhibited HCoV-OC43 coronavirus-infected cells during the attachment and penetration phases. Molecular docking and dynamics simulations exhibited that geraniin had a strong binding affinity and high stable binding to 3CLpro of SARS-CoV-2. Geraniin showed a strong inhibitory activity on coronavirus and may be a potential inhibitor of SARS-CoV-2 3CLpro.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / Tratamiento Farmacológico de COVID-19 Idioma: En Revista: Nat Prod Res Año: 2022 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / Tratamiento Farmacológico de COVID-19 Idioma: En Revista: Nat Prod Res Año: 2022 Tipo del documento: Article